MLSS
Milestone Scientific Inc.
There isn't enough reported data to score MLSS yet.
NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
MLSS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Unavailable | |
| Unavailable |
MLSS's revenue is currently healthy, but its profitability is under pressure. There isn't enough data to rate its cash flow and balance sheet.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
MLSS PE Valuation
MLSS has no meaningful PE right now: it lost money over the past year.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
MLSS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| High |
MLSS has the edge over NVO on the outlook, with more favorable earnings and profitability expectations.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
MLSS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.05 | +$0.04 |
| Q1 2026 | -$0.06 | +$0.01 |
| Q4 2025 | -$0.07 | $0.00 |
| Q3 2025 | -$0.08 | -$0.01 |
| Q2 2025 | -$0.09 | -$0.02 |
| Q1 2025 | -$0.07 | +$0.03 |
| Q4 2024 | -$0.07 | +$0.03 |
| Q3 2024 | -$0.07 | +$0.03 |
MLSS is still losing money, but far less than before: $0.05 per share over the past year, against $0.21 at its worst in mid-2020.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over MLSS on earnings quality, reporting a profit while its opponent remains loss making.
MLSS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $2.8M | +22% |
| Q1 2026 | $2.2M | -3.2% |
| Q4 2025 | $2.1M | +2.2% |
| Q3 2025 | $2.4M | -6.1% |
| Q2 2025 | $2.3M | +25% |
| Q1 2025 | $2.2M | -0.7% |
| Q4 2024 | $2M | -11% |
| Q3 2024 | $2.5M | +22% |
MLSS's revenue has held roughly level: $3M last quarter, up 22% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -37% | +27 points |
| Q1 2026 | -38% | +51 points |
| Q4 2025 | -52% | +49 points |
| Q3 2025 | -48% | +10 points |
| Q2 2025 | -64% | +32 points |
| Q1 2025 | -89% | -24 points |
| Q4 2024 | -101% | -14 points |
| Q3 2024 | -58% | +15 points |
MLSS's operating margin was −37% last quarter, up 27 points from the same quarter a year ago, near the top of its range since 2019.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over MLSS on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over MLSS on profitability, with a higher operating margin.
MLSS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$589.3K | +$1.2M |
| Q1 2026 | $85.2K | +$1.1M |
| Q4 2025 | -$229.2K | +$1.3M |
| Q2 2025 | -$1.8M | -325% |
| Q1 2025 | -$1M | +$210K |
| Q4 2024 | -$1.5M | -$265.7K |
| Q3 2024 | -$973.9K | +$79.3K |
| Q2 2024 | $783.7K | +$1.8M |
MLSS has the stronger cash trend. Its trailing FCF is up 46% versus its history, compared with NVO at down 14%.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO still generates free cash flow, though less than at its 2026 peak: $7.3B over the past year.
MLSS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +9.5% | +8.1M shares |
| 1 year | +13% | +11.1M shares |
| 3 years | +29% | +20.8M shares |
| 5 years | +35% | +23.9M shares |
| Available history | +95% | +45.4M shares |
MLSS has 93M diluted shares, up 13% from a year ago.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over MLSS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
MLSS Net Leverage
MLSS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
MLSS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.9 | Neutral |
| Stochastic | 4.7 | Oversold |
MLSS's weekly RSI is 38 (neutral) and its Stochastic is 5 (oversold).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
MLSS PE vs Healthcare Sector
MLSS has no meaningful PE right now: it lost money over the past year.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
MLSS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.33 | 12% below |
| 20 week MA | $0.39 | 26% below |
| 50 week MA | $0.35 | 17% below |
| 100 week MA | $0.57 | 49% below |
| 200 week MA | $0.70 | 59% below |
MLSS is in a downtrend: it's below all five of its weekly moving averages, and 59% below its 200-week average.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has the edge over MLSS on trend strength, trading above more of its moving averages.
MLSS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1.38 | $2.02 | +46% |
| 2021 | $2.02 | $2.13 | +5.4% |
| 2022 | $2.13 | $0.45 | -79% |
| 2023 | $0.45 | $0.69 | +53% |
| 2024 | $0.69 | $0.88 | +28% |
| 2025 | $0.88 | $0.29 | -67% |
| 2026 YTD | $0.29 | $0.29 | 0% |
MLSS has the edge over NVO on returns for 2026, with the stronger performance.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.